| Combinations | Number of studies | Number of patients with MPE/non-MPE | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | DOR (95% CI) | AUC (SEM) | Reference* |
| CEA + CA 125 | 3 | 107/167 | 0.65 (0.56 to 0.74) | 0.98 (0.94 to 0.99) | 25.20 (4.07 to 156.07) | 0.35 (0.21 to 0.57) | 66.01 (16.13 to 269.40) | 0.86 (0.10) | A1, A11, A20 |
| CEA + CA 15-3 | 3 | 208/366 | 0.66 (0.59 to 0.72) | 0.98 (0.96 to 0.99) | 26.37 (12.05 to 57.72) | 0.35 (0.29 to 0.43 | 86.1 (39.0 to 190.2) | 0.88 (0.12) | A3, A8, A23 |
| CEA + CA 19-9 | 1 | 65/142 | 0.46 | 1.00 | 132.17 (8.21 to 2128.70) | 0.54 (0.43 to 0.68) | 244.86 (14.62 to 41.0.90) | NA | A8 |
| CEA + CYFRA 21-1 | 3 | 97/115 | 0.72 (0.62 to 0.81) | 0.95 (0.89 to 0.98) | 8.89 (1.99 to 39.69) | 0.24 (0.08 to 0.68) | 48.48 (15.52 to 151.42) | 0.93 (0.03) | A11, A25, A28 |
| CA 125 + CA 19-9 | 1 | 19/42 | 0.95 | 0.98 | 38.79 (5.72 to 276.72) | 0.05 (0.01 to 0.36) | 738.00 (43.70 to 12464.20) | NA | A15 |
| CA 125 + CYFRA 21-1 | 2 | 115/133 | 0.66 (0.57 to 0.75) | 0.96 (0.90 to 0.98) | 17.9 (1.2 to 276.3) | 0.38 (0.28 to 0.54) | 45.0 (4.8 to 422.0) | NA | A11, A12 |
| CA 15-3 + CA 19-9 | 1 | 65/142 | 0.62 | 0.97 | 21.85 (8.16 to 58.50) | 0.40 (0.29 to 0.54) | 55.20 (18.14 to 167.93) | NA | A8 |
| CA 15-3 + CYFRA 21-1 | 2 | 87/109 | 0.83 (0.73 to 0.90) | 0.95 (0.90 to 0.99) | 19.03 (0.71 to 510.81) | 0.08 (0.00 to 4.35) | 345.53 (44.74 to 2668.80) | NA | A11, A15 |
| CEA + CA 125 + CYFRA 21-1 | 1 | 43/79 | 0.65 | 1.00 | 103.64 (6.48 to 1656.70) | 0.35 (0.24 to 0.53) | 292.35 (16.94 to 5046.60) | NA | A11 |
| CEA + CA 15-3 + CA 19-9 | 1 | 65/142 | 0.71 | 0.97 | 25.12 (9.44 to 66.85) | 0.30 (0.21 to 0.44) | 83.53 (27.02 to 258.23) | NA | A8 |
*Appendix references are available in online data supplement.
CI, confidence interval; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; AUC, area under curve; SEM, standard error of mean; NA, not applicable.